Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10752702
Anti-TIE2 antibodies and uses thereof
granted -
US 10751343
Nasal compositions stimulating ciliary activity
granted -
US 10752639
Bridged bicyclic inhibitors of menin-MLL and methods of use
granted -
US 10752920
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10751533
Regulation of autonomic control of bladder voiding after a complete spinal cord injury
granted -
US 10751416
IL-26 inhibitors
granted -
US 10751281
Auris formulations for treating otic diseases and conditions
granted -
US 10752626
Iso-citrate dehydrogenase (IDH) inhibitor
granted -
US 10752681
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 10758530
Carboxamide derivatives useful as rsk inhibitors
granted -
US 10759721
Deuterated CFTR potentiators
granted -
US 10758621
Liquid formulation comprising GM-CSF neutralizing compound
granted -
US 10758642
Sterilization process
granted -
US 10759759
Prodrugs of kallikrein inhibitors
granted -
US 10758629
Exon skipping oligomer conjugates for muscular dystrophy
granted -
US 10758632
NIR-conjugated tumor-specific antibodies and uses thereof
granted -
US 10759795
Aza-A-ring indenoisoquinoline topoisomerase I poisons
granted -
US 10759791
Mammalian and bacterial nitric oxide synthase inhibitors
granted -
US 10759808
Monofunctional intermediates for ligand-dependent target protein degradation
granted -
US 10759796
CXCR4 inhibitors and uses thereof
granted -
US 10759812
Thienopyrimidine derivative and use thereof in medicine
granted -
US 10759838
Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use
granted -
US 10759839
Cell-penetrating peptide
granted -
US 10759833
VMP-like sequences of pathogenic Borrelia species and strains
granted -
US 10759816
Heterocyclic compounds as RSV inhibitors
granted -
US 10759855
Antigen binding molecules to TIGIT
granted -
US 10759863
Modulation of γδ T cells
granted -
US 10759906
Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
granted -
US 10760048
In vitro production of medial ganglionic eminence precursor cells
granted -
US 10760055
Conditionally immortalized long-term stem cells and methods of making and using such cells
granted -
US 10760078
Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
granted -
US 10759768
Prophylactic or therapeutic agent for autism spectrum disorder
granted -
US 10758496
Estrogen receptor ligand treatment for neurodegenerative diseases
granted -
US 10758534
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 10758513
Modulators of mitochondrial protein import
granted -
US 10758526
Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
granted -
US 10758618
Pharmaceutical compositions comprising meloxicam
granted -
US 10758600
Fungal immunogens and related materials and methods
granted -
US 10758617
Pharmaceutical compositions comprising meloxicam
granted -
US 10758613
Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
granted -
US 10758614
Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
granted -
US 10758488
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
granted -
US 10758511
Stable analogs of CYP450 lipid metabolites and inhibitors of soluble epoxide hydrolase
granted -
US 10758595
Treatment of retinitis pigmentosa using engineered meganucleases
granted -
US 10758598
TPP-1 formulations and methods for treating CLN2 disease
granted -
US 10758619
Controlled release mucoadhesive systems
granted -
US 10759774
Inhibitors of hepatitis B virus targeting capsid assembly
granted -
US 10759793
2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.